The following trials provide information to treat various types of cancer and infectious disease, both for ongoing and completed clinical trials. For more information on our oncology therapy area please click here or for our infection therapy area please click here.
- collapse A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of the m-Tor Kinase Inhibitor AZD8055 Using Intermittent Dosing Schedules in Patients With Advanced Solid Malignancies and Lymphomas
- collapse A Phase I, Open-label, Single-center Study to Assess the Pharmacokinetics of Midazolam, a CYP3A4 Substrate, in Healthy Subjects When Administered Alone and in Combination With a Single Dose of 800-mg Vandetanib (CAPRELSA)
- collapse A Phase I, Open-label, Single-center Study to Assess the Pharmacokinetics of Digoxin in Healthy Subjects When Administered Alone and in Combination With a Single Dose of Vandetanib (CAPRELSA) 300 mg
- collapse A Phase I, Multi-centre, Two Part, Open Study to Assess the Safety and Tolerability of AZD2171 following Multiple Oral Doses in Patients with Relapsed or Refractory Acute Myeloid Leukaemia and Elderly Patients with De Novo or Secondary Acute Myeloid Leukaemia
- collapse A Phase I Single-centre 2-part Open Study to Assess the Safety and Tolerability of AZD2171 following Single and Multiple Oral Doses in Patients with Solid Malignant Tumours and Metastatic Liver Disease
- collapse A Phase I single-centre 2-part open study to assess the safety and tolerability of AZD2171 following single and multiple oral doses in patients with solid malignand tumours and metastatic liver disease
- collapse A Phase I, Open-label, Single-center Study to Assess the Pharmacokinetics of Metformin, an OCT2 Substrate, in Healthy Subjects When Administered Alone and in Combination With a Single Oral Dose of Vandetanib (CAPRELSA) 800 mg.
- collapse A Randomised, Open Label, Single Centre, 2 Way Crossover Bioequivalence Study Comparing Arimidex Tablet 1 mg and Anastrozole Orally Rapid Disintegration Film Formula 1 mg After Single Oral Administration in Japanese Healthy Male Subjects.
- collapse Phase I, Open-label, Dose-escalation Study to Assess Safety, Tolerability and Pharmacokinetics of MEDI-573 in Japanese Subjects
